Douglas M. Baker Jr. Named Independent Lead Director at Merck

News related to:Merck · 2 min read

Merck, known as MSD outside the United States and Canada, announced that Thomas H. Glocer will retire from the company's Board of Directors in May 2027. This decision comes after Glocer's long-standing tenure on the board, during which he provided invaluable expertise and counsel to the company. Glocer's retirement will mark the end of a significant chapter in Merck's governance, as he has been a trusted voice in the boardroom for many years.

Douglas M. Baker, Jr., a seasoned executive with extensive experience in corporate governance and organizational management, has been appointed as the independent lead director. Baker has served on the Merck Board of Directors since 2022 and brings a wealth of knowledge from his previous role as chairman and chief executive officer of Ecolab Inc., a provider of water and hygiene services and technologies for the food, hospitality, industrial, and energy markets. Additionally, Baker serves as a trustee of Mayo Clinic, further enhancing his credentials as a leader in the healthcare and business sectors.

Rob Davis, chairman and chief executive officer of Merck, expressed his gratitude to Glocer for his dedicated service.

Baker will take over the role of independent lead director, effective January 1, 2027.

The release also includes a forward-looking statement, which is a standard disclaimer in corporate communications. This statement notes that the news release includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

The statement further outlines several risks and uncertainties, including general industry conditions and competition, global trends toward health care cost containment, technological advances, new product development, and the company's ability to accurately predict future market conditions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2025, which is available on the Securities and Exchange Commission's website.

Start filing today

One press release free every week. No card required.

Create a free account